Tenax Therapeutics' Phase III LEVEL trial for its drug levosimendan did not meet the primary endpoint of overall patient improvement, leading Chardan Capital to downgrade the stock to Neutral from Buy. The trial aimed to improve patients' six-minute walk distance, but the drug's 14-meter improvement was not statistically significant compared to placebo. However, patients aged 74 and older showed a notable 37.6-meter improvement, and a key biomarker was reduced by 49%. The stock trades at $1.64 with a new price target of $5.00, reflecting cautious optimism despite the trial setback.
Tesla has increased its control of the U.S. electric vehicle (EV) market to 59%, marking its highest market share since 2023. This growth highlights Tesla's strong position and continued dominance in the competitive EV industry. The increased market ...
In June, President Donald Trump disclosed more than 1,000 financial transactions involving stocks, bonds, and ETFs, indicating a broad reshuffling of his investment portfolio. His transactions ranged between $78.1 million and $263.1 million, with pur...
Paramount issued a strong statement condemning actor Mark Ruffalo for using antisemitic tropes in his criticism of the company's $110 billion merger with Warner Bros. Ruffalo posted a video linking Oracle's technology to military efforts and accused ...
The Sandbox suspended SAND token bridging on Base and BNB Smart Chain after an attacker exploited the cross-chain system to mint unbacked tokens, isolating SAND on these networks. The Ethereum-based SAND remains secure and unaffected, with no user wa...
Microsoft reported $331 billion in annual revenue with Azure surpassing $100 billion, growing 41%. Its $678 billion contracted commercial backlog supports recurring revenue from AI and cloud services, fueling a 22% upside price target of $590.43. Des...
